Two simultaneous procedural developments are reshaping MDL 3092 in the Northern District of Ohio as we move through 2026, affecting thousands of patients who used Suboxone dissolvable film strips and suffered devastating tooth decay. With 17,911 federal Suboxone dental erosion lawsuits filed against Indivior as of June 2026 — and 1,827 cases currently pending in the MDL — the litigation has reached a critical mass that makes procedural compliance more important than ever. A June 2026 case management order established that 11% of future Suboxone settlements will be set aside for shared legal work and litigation costs, signaling that the court is actively building the infrastructure for eventual resolution. If you or someone you know took Suboxone sublingual film and experienced severe dental injuries, the coming months may determine whether your case survives at all.
What Is the Suboxone Lawsuit About?
The Suboxone lawsuit targets Indivior and its former parent company Reckitt Benckiser over allegations that the dissolvable sublingual film strips used to treat opioid use disorder contain a highly acidic formulation that erodes tooth enamel, causes severe decay, and leads to tooth loss — all without adequate warning to patients or prescribing physicians. Critically, the claims center on the film strips, not Suboxone tablets, which use a different delivery mechanism. The MDL has also recently expanded to include claims involving Sublocade injections, with plaintiffs alleging that the extended-release formulation caused similar dental injuries — a development that could significantly increase the overall scope of the litigation.
The litigation gained enormous momentum after the U.S. Food and Drug Administration issued a formal dental safety warning in January 2022, followed by a mandatory label update in June 2022 after hundreds of patient adverse-event reports flooded the agency. The FDA’s own analysis identified 305 dental injury cases directly linked to Suboxone film use, with alarming severity rates across the affected population. If you want a general sense of what these injuries may be worth as personal injury claims, a personal injury settlement calculator can provide a starting framework before you speak with legal counsel.
Core failure-to-warn claims remain active and are the legal backbone of MDL 3092. Earlier rulings narrowed some design-defect arguments, but the failure-to-warn theory — that Indivior and Reckitt Benckiser knew or should have known about the enamel-damaging properties of the acidic film and failed to disclose them — has survived. Daubert hearings on expert testimony concerning those enamel-damaging properties remain a key milestone as the litigation advances through 2026.
The Census-Form Deadline and What It Means for Your Case
Judge Philip Calabrese of the U.S. District Court for the Northern District of Ohio set a hard procedural census-form deadline for plaintiffs who filed their Suboxone lawsuits before 2025. Cases that missed that deadline now face a genuine risk of dismissal — not a theoretical one.
Census forms in mass tort MDLs serve a critical administrative function: they give the court and defendants verified, individual plaintiff data so the litigation can move forward efficiently. When census forms go unfiled, courts treat those cases as inactive or abandoned. Judge Calabrese has shown throughout MDL 3092 that procedural compliance is non-negotiable. If your attorney has not confirmed that your census form was submitted on time, that conversation needs to happen immediately. Because Suboxone dental injuries involve documented medical harm — extractions, crowns, root canals, full dentures — the damages at stake are substantial enough that procedural dismissal would be a preventable tragedy. A medical malpractice calculator can help illustrate the financial scope of those losses before you consult with an attorney.
With 17,911 federal lawsuits now on record and 1,827 cases active in the MDL as of mid-2026, the sheer volume of claims makes court administration increasingly complex. Procedural orders like the census-form requirement exist precisely to manage that complexity — and courts have little patience for noncompliance at this stage of the litigation.
Bundled Claims, Refiling Requirements, and the MDL’s Expanding Scope
A significant court order issued earlier in 2026 required thousands of bundled claims — cases in which multiple plaintiffs were grouped together in a single filing — to be refiled as individual lawsuits. This is a common procedural housekeeping measure in large MDLs, but it carries real consequences for plaintiffs whose attorneys fail to act. Missing the refiling window can result in a case being dismissed just as effectively as missing a census-form deadline.
If your case was part of a bundled filing, confirm with your attorney that an individual complaint has been submitted and that all supporting documentation — medical records, dental treatment history, prescription records — is properly attached. The court’s insistence on individualized filings reflects its broader effort to prepare the docket for the next phase of litigation, including bellwether trial selection.
Adding further complexity, the MDL has expanded to encompass claims involving Sublocade, Indivior’s extended-release injectable formulation of buprenorphine. Plaintiffs in those cases allege that Sublocade caused dental injuries similar to those associated with the sublingual film strips. Whether those claims will be litigated on the same track as the film-strip cases or managed separately remains to be seen, but the expansion signals that the court views the underlying liability theory — that Indivior failed to adequately warn about dental risks — as broadly applicable across its buprenorphine product line.
The 100-Case Core Discovery Pool and the Road to Bellwether Trials
Judge Calabrese has designated a core discovery pool of 100 representative cases to move through accelerated discovery in preparation for bellwether trials. Bellwether trials are the litigation’s proving ground: a small number of cases go to verdict first, and the outcomes — wins, losses, and damage amounts — send powerful signals to both sides about the value of the broader inventory and the viability of settlement.
The road to those trials runs through several remaining procedural milestones, including the completion of expert discovery, Daubert rulings on the parties’ scientific witnesses, and the formal selection of bellwether plaintiffs from the discovery pool. As of mid-2026, no court-approved settlements for Suboxone dental problems have been announced publicly, which means the litigation is still in its pretrial phase. The June 2026 case management order establishing an 11% common-benefit assessment on future settlements is a strong indicator, however, that the court and plaintiffs’ leadership are actively planning for the resolution phase — even if no global deal is imminent.
Common-benefit assessments are standard in MDL litigation. They ensure that the attorneys doing the heavy lifting of shared discovery, motion practice, and trial preparation are compensated from any eventual recovery, regardless of which individual firm represents a settling plaintiff. An 11% holdback on a litigation of this scale — nearly 18,000 federal cases — represents a significant financial commitment to the shared infrastructure of the case.
FDA Data: The Documented Scope of Suboxone Dental Harm
The FDA’s 2022 safety communication was not issued in a vacuum. Agency reviewers analyzed hundreds of adverse-event reports submitted through MedWatch and identified 305 cases of dental injury directly attributable to Suboxone sublingual film use. The injuries documented were severe: cavities, cracked teeth, tooth loss, and oral infections requiring surgical intervention. In many cases, patients reported that their dental problems emerged within months of starting Suboxone film therapy and progressed rapidly despite regular dental care.
What made the FDA findings particularly significant from a litigation standpoint was the agency’s conclusion that the dental injuries were not simply the result of patients’ pre-existing conditions or lifestyle factors — a defense Indivior has attempted to raise. The FDA’s analysis pointed directly to the acidic pH of the dissolving film as a causative mechanism, lending substantial scientific credibility to the plaintiffs’ core theory of harm.
That scientific foundation is what has allowed MDL 3092 to survive early dispositive motions and continue building toward trial. The Daubert hearings still pending in 2026 will test whether plaintiffs’ expert witnesses can present that causation theory in a form admissible at trial — a threshold that, if cleared, substantially increases settlement pressure on Indivior.
Who Qualifies to File a Suboxone Lawsuit?
Eligibility for a Suboxone dental injury lawsuit generally requires that a plaintiff meet the following criteria:
- Use of Suboxone sublingual film strips — not tablets or injectable formulations (though Sublocade claims are now being evaluated separately within the MDL)
- Documented dental injuries — including cavities, enamel erosion, cracked or broken teeth, tooth extraction, root canals, crowns, or full dentures
- A causal connection between film use and dental harm — typically established through medical and dental records showing the onset or acceleration of dental problems during or after Suboxone film therapy
- Filing within the applicable statute of limitations — which varies by state but is typically two to three years from the date the plaintiff knew or should have known that Suboxone caused their dental injuries
Patients who used Suboxone film under a valid prescription for opioid use disorder and subsequently experienced significant dental problems should consult with a mass tort attorney as soon as possible. With nearly 18,000 federal cases already filed as of 2026, the litigation is well established — but statutes of limitations are unforgiving, and delayed consultation can result in a valid claim becoming time-barred.
Frequently Asked Questions About the Suboxone Lawsuit
What is the current status of the Suboxone lawsuit MDL in 2026?
As of mid-2026, MDL 3092 in the Northern District of Ohio contains 1,827 active cases, while the total number of federal Suboxone dental erosion lawsuits filed against Indivior has reached 17,911. The litigation is in an advanced pretrial phase, with core discovery ongoing in a pool of 100 representative cases selected to prepare for bellwether trials. A June 2026 case management order established an 11% common-benefit assessment on future settlements, reflecting the court’s expectation that resolution — while not imminent — is being actively planned for. No court-approved settlements have been publicly announced as of August 2026. The MDL has also expanded to include claims involving Sublocade injections, broadening the scope of Indivior’s potential exposure.
What happens if I missed the Suboxone census-form deadline?
Missing the court-ordered census-form deadline creates a significant risk that your case will be dismissed. In MDL proceedings, census forms are not optional administrative paperwork — they are court-ordered submissions that establish your case as active and provide the defendants with the basic information needed to evaluate your claim. If you believe your census form was not submitted on time, contact your attorney immediately. Depending on the circumstances, there may be limited opportunities to seek relief from the court, but those windows close quickly and courts are generally unsympathetic to procedural failures in large MDLs where deadlines are clearly communicated well in advance.
What did the court’s bundled-claims order require plaintiffs to do?
Earlier in 2026, the court issued an order requiring plaintiffs whose cases had been filed as bundled multi-plaintiff complaints to refile as individual lawsuits. This is a standard MDL management tool that allows the court to assess each plaintiff’s claim on its individual merits and ensures that case-specific facts — the particular dental injuries suffered, the duration of Suboxone film use, the medical treatment required — are properly documented in a standalone complaint. Plaintiffs whose attorneys failed to meet the refiling deadline face the same dismissal risk as those who missed census-form deadlines. If your case was part of a bundled filing, verify with your legal team that an individual complaint has been submitted.
How do Suboxone sublingual film strips cause tooth damage?
Suboxone sublingual film strips dissolve under the tongue, where they are held in contact with tooth enamel for extended periods. The film’s formulation is highly acidic — plaintiffs allege that Indivior knew this and failed to warn patients or physicians. Prolonged exposure to an acidic environment demineralizes tooth enamel, the protective outer layer of the tooth. Once enamel is damaged, it does not regenerate, leaving the underlying dentin and pulp vulnerable to rapid decay, cracking, infection, and ultimately tooth loss. The FDA’s 2022 analysis confirmed this mechanism as the likely cause of the dental injuries reported by hundreds of Suboxone film users, which is why the agency required a mandatory label update disclosing the dental risk.
When will Suboxone lawsuit settlements happen, and how much could cases be worth?
As of August 2026, no court-approved Suboxone dental injury settlements have been publicly announced. The litigation is still working through pretrial discovery and moving toward bellwether trials, which will be the primary driver of any global settlement discussions. The June 2026 order establishing an 11% common-benefit assessment signals that the court and plaintiffs’ leadership are building the financial and procedural framework for eventual resolution, but a global settlement is unlikely before bellwether verdicts provide both sides with clear data on case values. Individual case values will depend on the severity of dental injuries, the extent of treatment required, lost wages, and pain and suffering. Cases involving full-mouth tooth loss or extensive reconstructive dental work may be worth significantly more than cases involving isolated cavities. A personal injury settlement calculator can provide a rough estimate, but consultation with an experienced mass tort attorney remains the most reliable way to assess the value of a specific claim.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.